Drug-induced Pulmonary Arterial Hypertension: a Review

Overview

Journal Heart Fail Rev

Date 2017 Apr 19

PMID 28417295

Citations 13

Authors

Lohit Garg

Ghulam Akbar

Sahil Agrawal

Manyoo Agarwal

Leila Khaddour

Rishin Handa

Aakash Garg

Mahek Shah

Brijesh Patel

Bhavinkumar D Dalal

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is a subgroup of PH patients characterized hemodynamically by the presence of pre-capillary PH, defined by a pulmonary artery wedge pressure (PAWP) ≤15 mmHg and a PVR >3 Wood units (WU) in the absence of other causes of pre-capillary PH. According to the current classification, PAH can be associated with exposure to certain drugs or toxins such as anorectic agents, amphetamines, or selective serotonin reuptake inhibitors. With the improvement in awareness and recognition of the drug-induced PAH, it allowed the identification of additional drugs associated with an increased risk for the development of PAH. The supposed mechanism is an increase in the serotonin levels or activation of serotonin receptors that has been demonstrated to act as a growth factor for the pulmonary artery smooth muscle cells and cause progressive obliteration of the pulmonary vasculature. PAH remains a rare complication of several drugs, suggesting possible individual susceptibility, and further studies are needed to identify patients at risk of drug-induced PAH.

Citing Articles

Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications.

Leiva O, Beaty W, Soo S, Agarwal M, Yang E Rev Cardiovasc Med. 2024; 25(3):87.

PMID: 39076943 PMC: 11263834. DOI: 10.31083/j.rcm2503087.

Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice.

Gurdogan M, Demir M, Yalta K, Gulertop Y Anatol J Cardiol. 2023; 27(6):299-307.

PMID: 37257013 PMC: 10250770. DOI: 10.14744/AnatolJCardiol.2023.3013.

An interesting case of pulmonary hypertension in nephrotic syndrome due to amphetamine use for attention-deficit hyperactivity disorder.

Khan A, Ubaid A, Hanif M, Jaiswal V, Gohar A, Mehta A Ann Med Surg (Lond). 2023; 85(5):1874-1877.

PMID: 37229094 PMC: 10205322. DOI: 10.1097/MS9.0000000000000355.

Giant pulmonary artery aneurysm caused by sibutramine-associated pulmonary arterial hypertension: First case in the literature.

Kultursay B, Keskin B, Karagoz A, Akbal O, Kaymaz C Anatol J Cardiol. 2021; 25(7):512-514.

PMID: 34236327 PMC: 8274892. DOI: 10.5152/AnatolJCardiol.2021.64166.

Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Liang S, Desai A, Black S, Tang H Adv Exp Med Biol. 2021; 1303:275-303.

PMID: 33788198 DOI: 10.1007/978-3-030-63046-1_15.

References

Collazos J, Martinez E, Fernandez A, Mayo J . Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med. 1996; 90(3):171-4. DOI: 10.1016/s0954-6111(96)90160-2. View

Ranchoux B, Gunther S, Quarck R, Chaumais M, Dorfmuller P, Antigny F . Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2014; 185(2):356-71. DOI: 10.1016/j.ajpath.2014.10.021. View

Stebel S, Wideman R . Pulmonary hemodynamic responses to intravenous prostaglandin E2 in broiler chickens. Poult Sci. 2007; 87(1):138-45. DOI: 10.3382/ps.2007-00334. View

Choubey D, Moudgil K . Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interferon Cytokine Res. 2011; 31(12):857-65. PMC: 3234493. DOI: 10.1089/jir.2011.0101. View

Das U . Possible role of prostaglandins in the pathogenesis of pulmonary hypertension. Prostaglandins Med. 1980; 4(3):163-70. DOI: 10.1016/0161-4630(80)90078-6. View

Chin K, Channick R, Rubin L . Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest. 2006; 130(6):1657-63. DOI: 10.1378/chest.130.6.1657. View

Simonneau G, Robbins I, Beghetti M, Channick R, Delcroix M, Denton C . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S43-S54. DOI: 10.1016/j.jacc.2009.04.012. View

Mukai M, Kondo M, Bohgaki T, Notoya A, Kohno M . Pulmonary veno-occlusive disease following allogeneic peripheral blood stem cell transplantation for chronic myeloid leukaemia. Br J Haematol. 2003; 123(1):1. DOI: 10.1046/j.1365-2141.2003.04423.x. View

Hong Z, Smith A, Archer S, Wu X, Nelson D, Peterson D . Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation. 2005; 112(10):1494-9. DOI: 10.1161/CIRCULATIONAHA.105.556704. View

10.

Schaiberger P, Kennedy T, Miller F, Gal J, Petty T . Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest. 1993; 104(2):614-6. DOI: 10.1378/chest.104.2.614. View

11.

Hoeper M, Bogaard H, Condliffe R, Frantz R, Khanna D, Kurzyna M . Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D42-50. DOI: 10.1016/j.jacc.2013.10.032. View

12.

Chambers C, Hernandez-Diaz S, Van Marter L, Werler M, Louik C, Jones K . Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006; 354(6):579-87. DOI: 10.1056/NEJMoa052744. View

13.

Williams L, Fussell S, Veith R, Nelson S, Mason C . Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Chest. 1996; 109(5):1388-91. DOI: 10.1378/chest.109.5.1388. View

14.

Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F . Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest. 2002; 121(3 Suppl):97S-98S. View

15.

Caravita S, Secchi M, Wu S, Pierini S, Paggi A . Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report. Cardiology. 2012; 120(4):187-9. DOI: 10.1159/000335064. View

16.

Rubin L . Primary pulmonary hypertension. N Engl J Med. 1997; 336(2):111-7. DOI: 10.1056/NEJM199701093360207. View

17.

Eddahibi S, Adnot S . Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res. 2002; 3:9. PMC: 64820. DOI: 10.1186/rr181. View

18.

Sacchi S, Kantarjian H, OBrien S, Cohen P, Pierce S, Talpaz M . Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol. 1995; 13(9):2401-7. DOI: 10.1200/JCO.1995.13.9.2401. View

19.

Cortelezzi A, Gritti G, Del Papa N, Pasquini M, Calori R, Gianelli U . Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia. 2007; 22(3):646-9. DOI: 10.1038/sj.leu.2404943. View

20.

Hertzman P, Falk H, Kilbourne E, Page S, SHULMAN L . The eosinophilia-myalgia syndrome: the Los Alamos Conference. J Rheumatol. 1991; 18(6):867-73. View